Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$1.6 million.

  • Revolution Medicines' Cash from Financing Activities fell 102.06% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 22.13%. This contributed to the annual value of $959.4 million for FY2024, which is 21.95% down from last year.
  • Revolution Medicines' Cash from Financing Activities amounted to -$1.6 million in Q3 2025, which was down 100.62% from $256.6 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Cash from Financing Activities registered a high of $873.8 million during Q4 2024, and its lowest value of -$1.6 million during Q3 2025.
  • Its 3-year average for Cash from Financing Activities is $222.2 million, with a median of $64.6 million in 2023.
  • As far as peak fluctuations go, Revolution Medicines' Cash from Financing Activities spiked by 106,196.72% in 2023, and later crashed by 102.06% in 2025.
  • Revolution Medicines' Cash from Financing Activities (Quarterly) stood at $10.7 million in 2021, then skyrocketed by 378.78% to $51.4 million in 2022, then soared by 1,534.16% to $839.4 million in 2023, then increased by 4.10% to $873.8 million in 2024, then crashed by 102.06% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, $256.6 million for Q2 2025, and $874,000 during Q1 2025.